WHO fracture risk calculator (FRAX™) in the assessment of obese patients with osteoporosis

Endokrynologia Polska

Volumn 60, Issue 2, 2009, Pages 82-87

  Franek, Edward ^a,b   Wichrowska, Hanna ^a   Gozdowski, Dariusz ^c   Puzianowska Kuźnicka, Monika ^b  

^a CSK MSWiA ^*  (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

10 years fracture risk; Fracture; FRAX ; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; VITAMIN D;

AGE DISTRIBUTION; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE RISK CALCULATOR; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; OUTPATIENT CARE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT PLANNING;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CLODRONIC ACID; COMORBIDITY; FEMALE; FRACTURES, BONE; HUMANS; OBESITY; OSTEOPOROSIS; POLAND; RISK ASSESSMENT; VITAMIN D; WORLD HEALTH ORGANIZATION;

EID: 65749087043     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kanis JA. Osteoporosis III: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936.
2. Zuckerman JD. Hip fracture. N Engl J Med 1996; 334: 1519-1525.
3. Ray NF, Chan JK, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35.
4. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Mineral Res 2007; 22: 465-75.
5. Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clinical fracture. Osteoporosis Int 2000; 7: 556-561.
6. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density (BMD) predict occurrence of osteoporotic fracture. Br Med J 1996; 312: 1254-1259.
7. Siris E, Delmas PD. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporosis Int 2008; 19: 383-384.
8. http://www.shef.nc.uk
9. Lorene R, Gluszko R, Karczmarewicz E et al. Recommendations on the diagnosis and treatment of osteoporosis. Reducing the incidence of fractures through effective prevention and treatment. 2007. http://www.io-fbonehealth.org/health-professionals/national- regional-guidelines/references.html#ref_24.
10. Kanis JA, Burlet N, Cooper C et al. European guidelines for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2008; 19: 399-428.
11. Kanis JA, McCloskey EV, Johansson H et al. Case finding for the management of osteoporosis with FRAX® - assessment and intervention thresholds for the UK. Osteoporosis Int 2008; 19: 1395-1408.
12. Bone HG, Hosking D, Devogelaer J-P et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199.
13. Mellstroem DD, Sorensen OH, Goemaere S et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462-468.
14. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX) randomized trial. JAMA 2006; 296: 2927-2938.
15. Reginster J-Y, Minne HW, Sorenses OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83-91.
16. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1341.
17. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metabol 2000; 85: 4118-4124.
18. Harris ST, Watts NB, Genant HIK et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 1999; 282: 1344-1352.
19. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-645.
20. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468.
21. Reginster JY, Seeman E, De Vemejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005; 90: 2816-2822.
22. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-340.
23. Black DM, Delmas PD, Eastell R et al. Once yearly zoledronic-acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
24. Czerwinski E, Kanis JA, Trybulec B et al. The incidence and risk of hip fracture in Poland. Osteoporosis Int 2008, DOI 10.1007/s00198-008-0787-8.